Signaling through JAM-1 and αvβ3 is required for the angiogenic action of bFGF: Dissociation of the JAM-1 and αvβ3 complex

Blood

Volumn 102, Issue 6, 2003, Pages 2108-2114

  Naik, Meghna U ^b   Mousa, Shaker A ^b   Parkos, Charles A ^b   Naik, Ulhas P ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; GROWTH FACTOR RECEPTOR; INTEGRIN; JUNCTIONAL ADHESION MOLECULE A; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL JUNCTION; CELL PROLIFERATION; CELL STRUCTURE; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; METASTASIS; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0141679018     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-04-1114     Document Type: Article

References (42)

1. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1: 27-31.
3. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 1997;79:1-8.
4. 3 for angiogenesis. Science. 1994;264:569-571.
5. Hynes RO, Bader BL. Hodivala-Dilke K. Integrins in vascular development. Braz J Med Biol Res. 1999;32:501-510.
6. Ribatti D, Urbinati C, Nico B, Rusnati M, Roncali L, Presta M. Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. Dev Biol. 1995;170:39-49.
7. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380:435-439.
8. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev. 1997;18:26-45.
9. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multi-functional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001;28:620-625.
10. Gonzalez RP, Soares FS, Farias RF, et al. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea. Biol Pharm Bull. 2001;24:151-154.
11. 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci. 1995;108:2655-2661.
12. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995;270:1500-1502.
13. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J Sci Am. 2000;6(suppl 3):S245-S249.
14. 3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998;140:1255-1263.
15. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
16. 3. Clin Cancer Res. 2000;6: 3056-3061.
17. Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-2238.
18. Naik UP, Naik MU, Eckfeld K, Martin-DeLeon P, Spychala J. Characterization and chromosomal localization of JAM-1, a platelet receptor for a stimulatory monoclonal antibody. J Cell Sci. 2001;114:539-547.
19. Liu Y, Nusrat A. Schnell FJ, et al. Human junction adhesion molecule regulates tight junction resealing in epithelia. J Cell Sci. 2000;113:2363-2374.
20. Naik UP, Patel PM, Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphal1b cytoplasmic domain. J Biol Chem. 1997;272:4651-4654.
21. Keely PJ, Fong AM, Zutter MM, Santoro SA. Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci. 1995;108:595-607.
22. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8:27-34.
23. Benelli R, Albini A. In vitro models of angiogenesis: the use of Matrigel. Int J Biol Markers. 1999;14:243-246.
24. Aplin AE, Short SM, Juliano RL. Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains. J Biol Chem. 1999;274:31223-31228.
25. Martin-Padura I, Lostaglio S, Schneemann M, et al. Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol. 1998;142: 117-127.
26. Kevil CG, Payne DK, Mire E, Alexander JS. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins. J Biol Chem. 1998;273:15099-15103.
27. Suarez S, Ballmer-Hofer K. VEGF transiently disrupts gap junctional communication in endothelial cells. J Cell Sci. 2001;114:1229-1235.
28. Wright TJ, Leach L, Shaw PE, Jones P. Dynamics of vascular endothelial-cadherin and beta-catenin localization by vascular endothelial growth factor-induced angiogenesis in human umbilical vein cells. Exp Cell Res. 2002;280:159-168.
29. Tanaka K, Abe M, Sato Y. Roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the signal transduction of basic fibroblast growth factor in endothelial cells during angiogenesis. Jpn J Cancer Res. 1999;90: 647-654.
30. Ozaki H, Ishii K, Horiuchi H, et al. Cutting edge: combined treatment of TNF-alpha and IFN-gamma causes redistribution of junctional adhesion molecule in human endothelial cells. J Immunol. 1999;163:553-557.
31. Shaw SK, Perkins BN, Lim YC, et al. Reduced expression of junctional adhesion molecule and platelet/endothelial cell adhesion molecule-1 (CD31) at human vascular endothelial junctions by cytokines tumor necrosis factor-alpha plus interferon-gamma does not reduce leukocyte transmigration under flow. Am J Pathol. 2001;159: 2281-2291.
32. Ostermann G, Weber KS, Zernecke A, Schroder A, Weber C. JAM-1 is a ligand of the beta2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002;3:151-158.
33. Aurrand-Lions M, Johnson-Leger C, Wong C, Du Pasquier L, Imhof BA. Heterogeneity of endothelial junctions is reflected by differential expression and specific subcellular localization of the three JAM family members. Blood. 2001;98:3699-3707.
34. Carron CP, Meyer DM, Pegg JA, et al. A peptido-mimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 1998;58:1930-1935.
35. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999;103:47-54.
36. Rehn M, Veikkola T, Kukk-Valdre E, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A. 2001;98: 1024-1029.
37. Haubner R, Wester HJ, Reuning U, et al. Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med. 1999;40:1061-1071.
38. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 1998;95:507-519.
39. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin - deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103:229-238.
40. Huang X, Griffiths M, Wu J, Farese RV Jr, Sheppard D. Normal development, wound healing, and adenovirus susceptibility in beta5-deficient mice. Mol Cell Biol. 2000;20:755-759.
41. Stupack DG, Cheresh DA. Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci. 2002;115:3729-3738.
42. Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med. 2002;8:193-194.